ArticleBMC ophthalmology2026
Retreatment using LASIK, PRK, or ICL for myopic regression after corneal laser refractive surgery.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the outcomes of retreatment for myopic regression following primary LASIK or PRK, and to explore factors associated with pre-retreatment refractive error.
methodsRetrospective cross-sectional study of eyes undergoing retreatment with LASIK, PRK, or ICL implantation after prior LASIK/PRK. Outcomes included UDVA, CDVA, MRSE, and safety and efficacy indices through 6-12 months. Associations between baseline factors and pre-retreatment MRSE were assessed.
results158 eyes were included (136 LASIK, 12 PRK, 10 ICL). Early postoperative outcomes improved significantly for LASIK (UDVA 0.37 to 0.04 logMAR; MRSE - 1.28 D to - 0.12 D) and ICL (UDVA 0.68 to 0.03 logMAR; MRSE - 2.72 D to 0.03 D). PRK also produced significant UDVA gains (0.63 to 0.06 logMAR). Efficacy and safety indices were near or above 1.0 across groups. A longer interval since primary surgery was significantly linked to more negative MRSE, consistent with greater regression. Mild correlation between pre-retreatment MRSE and age, initial MRSE, and tissue ablation were observed. Complications were low (7.9%).
conclusionsRetreatment for myopic regression with LASIK, PRK, or ICL was safe and effective, with stable outcomes through 6-12 months. Regression was multifactorial and not predicted by baseline characteristics, though longer intervals between surgeries were significantly associated with greater myopic regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.